Every earnings call for TATVA — management tone, guidance, KPIs and promise tracking, quarter by quarter.
TATVA · 6 transcripts · Chemicals · latest Q1 FY27Tatva Chintan Pharma Chem Limited has 6 earnings calls on record here, a Chemicals company, most recently Q1 FY27. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Operating Revenue ₹167 cr (+43% YoY); EBITDA ₹32 cr (+86% YoY). Operating revenue grew 43% YoY to INR 167.1 crores.
Read full transcript & analysisOperating Revenue ₹134 cr (+24% YoY); EBITDA ₹28 cr (+214% YoY); EBITDA Margin 20.95%. Operating revenue grew 24% YoY to INR 134.1 crores in Q4 FY26.
Read full transcript & analysisOperating Revenue 1313 million (+53% YoY); EBITDA 255 million (+261% YoY). Operating revenue of INR1,313 million, up 53% YoY.
Read full transcript & analysisRevenue 1313 million (+53% YoY); EBITDA 255 million (+261% YoY). Operating revenue of INR1,313 million, up 53% YoY and 6% QoQ.
Read full transcript & analysisOperating Revenue 1169 million (+11% YoY); EBITDA 173 million (+37% YoY); EBITDA Margin 14.8% (+24% YoY). Operating revenue grew 11% YoY to INR1,169 million.
Read full transcript & analysisRevenue from Operations 1168 million (+11% YoY); EBITDA 173 million (+37% YoY); EBITDA Margin 14.8%. Operating revenue of INR 1,169 million, up 11% YoY and 8% QoQ.
Read full transcript & analysis